Literature DB >> 16697358

Heart muscle engineering: an update on cardiac muscle replacement therapy.

Wolfram-Hubertus Zimmermann1, Michael Didié, Stephan Döker, Ivan Melnychenko, Hiroshi Naito, Christina Rogge, Malte Tiburcy, Thomas Eschenhagen.   

Abstract

Cardiac muscle engineering aims at providing functional myocardium to repair diseased hearts and model cardiac development, physiology, and disease in vitro. Several enabling technologies have been established over the past 10 years to create functional myocardium. Although none of the presently employed technologies yields a perfect match of natural heart muscle, it can be anticipated that human heart muscle equivalents will become available after fine tuning of currently established tissue engineering concepts. This review provides an update on the state of cardiac muscle engineering and its utilization in cardiac regeneration. We discuss the application of stem cells including the allocation of autologous cell material, transgenic technologies that may improve tissue structure as well as in vivo engraftment, and vascularization concepts. We also touch on legal and economic aspects that have to be considered before engineered myocardium may eventually be applied in patients and discuss who may be a potential recipient.

Entities:  

Mesh:

Year:  2006        PMID: 16697358     DOI: 10.1016/j.cardiores.2006.03.023

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  49 in total

1.  Intravital microscopy to study myocardial engraftment.

Authors:  Entela B Lushaj; Jian Hu; Robert Haworth; Lucian Lozonschi
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-03-28

Review 2.  Getting to the heart of tissue engineering.

Authors:  Luda Khait; Louise Hecker; Nicole R Blan; Garrett Coyan; Francesco Migneco; Yen-Chih Huang; Ravi K Birla
Journal:  J Cardiovasc Transl Res       Date:  2008-01-29       Impact factor: 4.132

3.  Engineered fetal cardiac graft preserves its cardiomyocyte proliferation within postinfarcted myocardium and sustains cardiac function.

Authors:  Kazuro L Fujimoto; Kelly C Clause; Li J Liu; Joseph P Tinney; Shivam Verma; William R Wagner; Bradley B Keller; Kimimasa Tobita
Journal:  Tissue Eng Part A       Date:  2011-01-16       Impact factor: 3.845

Review 4.  Muscle-derived stem cells for tissue engineering and regenerative therapy.

Authors:  Arvydas Usas; Johnny Huard
Journal:  Biomaterials       Date:  2007-12       Impact factor: 12.479

Review 5.  Strategies for tissue engineering cardiac constructs to affect functional repair following myocardial infarction.

Authors:  Kathy Yuan Ye; Lauren Deems Black
Journal:  J Cardiovasc Transl Res       Date:  2011-08-05       Impact factor: 4.132

6.  Is tissue engineering a new paradigm in medicine? Consequences for the ethical evaluation of tissue engineering research.

Authors:  Leen Trommelmans; Joseph Selling; Kris Dierickx
Journal:  Med Health Care Philos       Date:  2009-07-24

Review 7.  Micro- and nanoscale control of the cardiac stem cell niche for tissue fabrication.

Authors:  Bari Murtuza; Jason W Nichol; Ali Khademhosseini
Journal:  Tissue Eng Part B Rev       Date:  2009-12       Impact factor: 6.389

8.  Co-culture induces alignment in engineered cardiac constructs via MMP-2 expression.

Authors:  Jason W Nichol; George C Engelmayr; Mingyu Cheng; Lisa E Freed
Journal:  Biochem Biophys Res Commun       Date:  2008-06-16       Impact factor: 3.575

9.  Scaffold-free vascular tissue engineering using bioprinting.

Authors:  Cyrille Norotte; Francois S Marga; Laura E Niklason; Gabor Forgacs
Journal:  Biomaterials       Date:  2009-08-06       Impact factor: 12.479

10.  A three-dimensional gel bioreactor for assessment of cardiomyocyte induction in skeletal muscle-derived stem cells.

Authors:  Kelly C Clause; Joseph P Tinney; Li J Liu; Burhan Gharaibeh; Johnny Huard; Jonathan A Kirk; Sanjeev G Shroff; Kazuro L Fujimoto; William R Wagner; John C Ralphe; Bradley B Keller; Kimimasa Tobita
Journal:  Tissue Eng Part C Methods       Date:  2010-06       Impact factor: 3.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.